[ET Net News Agency, 4 June 2025]  CSPC PHARMA (01093) rose 5% to HK$8.12.
  It hits an intra-day high of HK$8.14, and an intra-day low of HK$7.72. The total shares 
traded was 71.21 million, with a value of HK$567.61m. The active buy/sell ratio is 56:44, 
with net buying turnover of HK$62.9m. CHINA INNOVATION MARKET SER accounts for greatest 
net responsive buying turnover of HK$19.08m, with volume weighted average price of  
HK$7.999. J.P. MORGAN BRO (HK) accounts for greatest net responsive selling turnover of 
HK$18.96m, with volume weighted average price of HK$7.949. The stock has risen a combined 
6.7% over the past 2 consecutive trading days.
  The Hang Seng Index now rose 185 points, or 0.8% to 23,697; the Hang Seng China 
Enterprises Index now rose 73 points, or 0.9% to 8,593. 
  
          Basic Information 
          ================= 
  
  ----------------------------------
  Nominal    8.120 % Chg     +5.05% 
  High       8.140 Low        7.720 
  Shares Tr 71.21m Turnover 567.61m 
  10-D SMA   7.184 %H.V      61.364 
  20-D SMA   6.474 VWAP       7.971 
  50-D SMA   5.800 RSI14     76.029 
  ----------------------------------
Status: Active buy/sell ratio is 56:44, with net buying turnover of HK$62.9m, rising a  
combined 6.7% over the past 2 consecutive trading days
  
Performance of stocks in the same sector or of relevance
========================================================
  
  Stock (Code)            Price (HK$) Change (%)
  ----------------------------------------------- 
  CSPC PHARMA (01093)            8.12      +5.05
  SINOPHARM (01099)             19.02      -0.21
  SINO BIOPHARM (01177)          4.65      +3.79
  INNOVENT BIO (01801)          73.85     +13.53
  WUXI BIO (02269)              25.00      +1.21
  WUXI APPTEC (02359)           70.70      +0.28
  CHINARES PHARMA (03320)        5.18      +0.19
  HANSOH PHARMA (03692)         26.70      +0.75
  BEIGENE (06160)              156.10      +3.17
  AKESO (09926)                 82.05      +1.67
  ----------------------------------------------- 
  (ed)



 
 